Follow
“The opportunity of providing the full complexity and spectrum of sound in children born with profound genetic deafness is a phenomenon I did not expect to see in my lifetime,” said Lawrence R. Lustig, M.D., Chair of Columbia University’s Department of Otolaryngology”
Regeneron, maker of the gene therapy Covid treatment REVEN-Cov, announces children with generic deafness in gene therapy clinical trial have seen an 80 db increase in their ability to hear within months.